Q-omics provides the consensus-scored ST3GAL3 profile across patient tissues and cancer cell-line models. ST3GAL3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ST3GAL3 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, ST3GAL3 RNA expression shows 19,871 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where ST3GAL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST3GAL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST3GAL3 survival associations across molecular data types. ST3GAL3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST3GAL3 RNA expression–survival associations across cancer types. High ST3GAL3 expression shows unfavorable associations in ACC, KICH, LGG, MESO and LUSC, but favorable associations in UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ST3GAL3 RNA expression.
This table summarizes ST3GAL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ST3GAL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST3GAL3 shows lower tumor expression in BLCA, THCA, UCEC, BRCA and LUAD and higher tumor expression in LIHC. The BLCA box plot shows higher ST3GAL3 RNA expression in normal versus tumor tissue (log2 FC = −2.262, t-test p < 0.001).
This table shows molecular features associated with ST3GAL3 in patient tissues and cancer cell lines. In patient samples, ST3GAL3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ST3GAL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
